194 related articles for article (PubMed ID: 36287217)
1. One-Year Romosozumab Treatment Followed by One-Year Denosumab Treatment for Osteoporosis in Patients on Hemodialysis: An Observational Study.
Saito T; Mizobuchi M; Kato T; Suzuki T; Fujiwara Y; Kanamori N; Makuuchi M; Honda H
Calcif Tissue Int; 2023 Jan; 112(1):34-44. PubMed ID: 36287217
[TBL] [Abstract][Full Text] [Related]
2. Effects after starting or switching from bisphosphonate to romosozumab or denosumab in Japanese postmenopausal patients.
Shimizu T; Arita K; Murota E; Hiratsuka S; Fujita R; Ishizu H; Asano T; Takahashi D; Takahata M; Iwasaki N
J Bone Miner Metab; 2021 Sep; 39(5):868-875. PubMed ID: 33847831
[TBL] [Abstract][Full Text] [Related]
3. Effects of prior osteoporosis treatment on the treatment response of romosozumab followed by denosumab in patients with postmenopausal osteoporosis.
Ebina K; Etani Y; Tsuboi H; Nagayama Y; Kashii M; Miyama A; Kunugiza Y; Hirao M; Okamura G; Noguchi T; Takami K; Goshima A; Miura T; Fukuda Y; Kurihara T; Okada S; Nakata K
Osteoporos Int; 2022 Aug; 33(8):1807-1813. PubMed ID: 35362725
[TBL] [Abstract][Full Text] [Related]
4. Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Nakata K; Okada S
Joint Bone Spine; 2021 Oct; 88(5):105219. PubMed ID: 34020048
[TBL] [Abstract][Full Text] [Related]
5. Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis.
Kashii M; Kamatani T; Nagayama Y; Miyama A; Tsuboi H; Ebina K
Osteoporos Int; 2023 Mar; 34(3):563-572. PubMed ID: 36585509
[TBL] [Abstract][Full Text] [Related]
6. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis.
Ebina K; Hirao M; Tsuboi H; Nagayama Y; Kashii M; Kaneshiro S; Miyama A; Nakaya H; Kunugiza Y; Okamura G; Etani Y; Takami K; Goshima A; Nakata K
Bone; 2020 Nov; 140():115574. PubMed ID: 32777516
[TBL] [Abstract][Full Text] [Related]
7. Effect of low dose denosumab on bone mineral density in postmenopausal women with osteoporosis after a transition from 60 mg dose: a prospective observational study.
Khan AA; AbuAlrob H; M'Hiri I; Ali DS; Dandurand K; Said H; Alkassem H; Hakami Y; Hweija I; Iqbal S; Romanovschi M; Mehmood S; Zariffeh H; Guyatt G; Ibrahim Q; Brignardello-Petersen R; Syed HI
Endocrine; 2023 Jun; 80(3):647-657. PubMed ID: 37186270
[TBL] [Abstract][Full Text] [Related]
8. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension.
Miyauchi A; Dinavahi RV; Crittenden DB; Yang W; Maddox JC; Hamaya E; Nakamura Y; Libanati C; Grauer A; Shimauchi J
Arch Osteoporos; 2019 Jun; 14(1):59. PubMed ID: 31168657
[TBL] [Abstract][Full Text] [Related]
9. Denosumab versus romosozumab for postmenopausal osteoporosis treatment.
Kobayakawa T; Miyazaki A; Saito M; Suzuki T; Takahashi J; Nakamura Y
Sci Rep; 2021 Jun; 11(1):11801. PubMed ID: 34083636
[TBL] [Abstract][Full Text] [Related]
10. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study.
Kobayakawa T; Miyazaki A; Takahashi J; Nakamura Y
Bone; 2022 Sep; 162():116480. PubMed ID: 35787482
[TBL] [Abstract][Full Text] [Related]
11. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
Shane E; Shiau S; Recker RR; Lappe JM; Agarwal S; Kamanda-Kosseh M; Bucovsky M; Stubby J; Cohen A
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1528-e1540. PubMed ID: 34849989
[TBL] [Abstract][Full Text] [Related]
12. Comparable efficacy of denosumab and romosozumab in patients with rheumatoid arthritis receiving glucocorticoid administration.
Kobayakawa T; Miyazaki A; Kanayama Y; Hirano Y; Takahashi J; Suzuki T; Nakamura Y
Mod Rheumatol; 2023 Jan; 33(1):96-103. PubMed ID: 35234889
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of romosozumab in patients with osteoporosis at high fracture risk: a Japanese real-world study.
Miyauchi A; Hamaya E; Shimauchi J; Yoshinaga Y; Nishi K
J Bone Miner Metab; 2024 Jan; 42(1):77-89. PubMed ID: 38086988
[TBL] [Abstract][Full Text] [Related]
14. Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab.
Kendler DL; Bone HG; Massari F; Gielen E; Palacios S; Maddox J; Yan C; Yue S; Dinavahi RV; Libanati C; Grauer A
Osteoporos Int; 2019 Dec; 30(12):2437-2448. PubMed ID: 31628490
[TBL] [Abstract][Full Text] [Related]
15. Effects of 24 Months of Treatment With Romosozumab Followed by 12 Months of Denosumab or Placebo in Postmenopausal Women With Low Bone Mineral Density: A Randomized, Double-Blind, Phase 2, Parallel Group Study.
McClung MR; Brown JP; Diez-Perez A; Resch H; Caminis J; Meisner P; Bolognese MA; Goemaere S; Bone HG; Zanchetta JR; Maddox J; Bray S; Grauer A
J Bone Miner Res; 2018 Aug; 33(8):1397-1406. PubMed ID: 29694685
[TBL] [Abstract][Full Text] [Related]
16. Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study.
Tominaga A; Wada K; Okazaki K; Nishi H; Terayama Y; Kato Y
Osteoporos Int; 2021 Oct; 32(10):1999-2009. PubMed ID: 33770201
[TBL] [Abstract][Full Text] [Related]
17. One Year of Romosozumab Followed by Two Years of Denosumab Maintains Fracture Risk Reductions: Results of the FRAME Extension Study.
Lewiecki EM; Dinavahi RV; Lazaretti-Castro M; Ebeling PR; Adachi JD; Miyauchi A; Gielen E; Milmont CE; Libanati C; Grauer A
J Bone Miner Res; 2019 Mar; 34(3):419-428. PubMed ID: 30508316
[TBL] [Abstract][Full Text] [Related]
18. Comparison of romosozumab versus denosumab treatment on bone mineral density after 1 year in rheumatoid arthritis patients with severe osteoporosis: A randomized clinical pilot study.
Mochizuki T; Yano K; Ikari K; Hiroshima R; Okazaki K
Mod Rheumatol; 2023 Apr; 33(3):490-495. PubMed ID: 35689558
[TBL] [Abstract][Full Text] [Related]
19. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
20. Meta-analysis of the effects of denosumab and romosozumab on bone mineral density and turnover markers in patients with osteoporosis.
Hu M; Zhang Y; Guo J; Guo C; Yang X; Ma X; Xu H; Xiang S
Front Endocrinol (Lausanne); 2023; 14():1188969. PubMed ID: 37529613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]